SANF Share Price

Open 74.70 Change Price %
High 74.80 1 Day -0.90 -1.21
Low 73.75 1 Week -2.25 -2.96
Close 73.75 1 Month -1.75 -2.32
Volume 823 1 Year -2.85 -3.72
52 Week High 78.80
52 Week Low 65.00
SANF Important Levels
Resistance 2 74.72
Resistance 1 74.32
Pivot 74.10
Support 1 73.18
Support 2 72.78
BIT Italy Most Active Stocks
ISP 2.29 -4.58%
RN 0.05 0.00%
RN 0.05 0.00%
TIT 0.83 -1.19%
PMI 0.36 0.00%
PMI 0.36 0.00%
SPM 0.49 -2.00%
SPM 0.49 -2.00%
G 15.55 9.12%
G 15.55 9.12%
More..
BIT Italy Top Gainers Stocks
ZUC 0.04 33.33%
FUL 2.31 23.53%
FUL 2.31 23.53%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
TAS 4.80 17.65%
TAS 4.80 17.65%
TAS 4.80 17.65%
More..
BIT Italy Top Losers Stocks
SPMR 5.41 -9.83%
MN 1.38 -4.83%
MN 1.38 -4.83%
ISP 2.29 -4.58%
FNM 0.53 -3.64%
FNM 0.53 -3.64%
DIA 54.40 -3.37%
DIA 54.40 -3.37%
DIA 54.40 -3.37%
MIT 1.44 -3.36%
More..

Sanofi (BIT: SANF)

SANF Technical Analysis 2
As on 24th Jan 2017 SANF Share Price closed @ 73.75 and we RECOMMEND Buy for LONG-TERM with Stoploss of 72.86 & Strong Sell for SHORT-TERM with Stoploss of 76.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
SANF Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SANF Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.sanofi-aventis.com
SANF Address
SANF
54, Rue La Bo
Paris, 75008
France
Phone: 33 1 53 77 40 00
SANF Latest News
FDA files case against Sanofi   The Standard   - 24th Jan 17
Flat Prospects for Sanofi in the Near Future? (SNY)   Investopedia   - 23rd Jan 17
Lexicon developing type 1 diabetes treatment with Sanofi   Medical Marketing and Media   - 23rd Jan 17
Enteris BioPharma signs oral diabetes pact with Sanofi   FierceBiotech   - 23rd Jan 17
Sanofi: Availability of the Pre-quarterly Results Communication   Yahoo Finance   - 23rd Jan 17
Sanofi's M&A misses frustrate some investors in drugmaker   Reuters   - 20th Jan 17
Rebooted Merrimack names Sanofi Genzyme SVP as CEO   FierceBiotech   - 19th Jan 17
Is Praluent doomed? Regeneron, Sanofi appeal for a reprieve, but experts are ...   FiercePharma   - 17th Jan 17
Sanofi, ImmuNext In $500M Autoimmune Drug Deal (SNY)   Investopedia   - 13th Jan 17
Sanofi investors count cost of Praluent ruling   MarketWatch   - 06th Jan 17
Interactive Technical Analysis Chart Sanofi ( SANF BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Sanofi
SANF Business Profile
Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Its products include Lantus and Apidra analogs of human insulin; Insuman human insulin solutions and suspensions; Amaryl, a sulfonylurea; BGStar, iBGStar, and MyStar Extra blood glucose meters; enzyme replacement therapies, such as Cerezyme for Gaucher disease, Fabrazyme for Fabry, and Myozyme/Lumizyme for Pompe disease; Aldurazyme, for mucopolysaccharidosis Type I; Aubagio, a immunomodulator for multiple sclerosis; Taxotere, a taxane derivative for cancers; Eloxatine for colorectal cancer; and Jevtana for prostate cancer. The company’s products also comprise thrombosis medicines, such as Plavix anti-platelet agent for atherothrombotic conditions and Lovenox to prevent and treat deep vein thrombosis; and cardiovascular medicines, including Multaq anti-arrhythmic agent and Aprovel/CoAprovel for hypertension treatments. It also offers Renagel/Renvela for patients with chronic kidney disease on dialysis to treat high phosphorus levels; Synvisc and Synvisc-One viscosupplements to treat pain associated with osteoarthritis; and pediatric and influenza, adult and adolescent booster, meningitis and pneumonia, and travel and endemics vaccines. In addition, the company provides pharmaceuticals and vaccines used by veterinarians, farmers, and pet owners; consumer health care products; and generic medicines. Sanofi distributes its products through its sales force, as well as through physicians, pharmacies, hospitals, distributors, veterinaries, chemists, and wholesalers. It has strategic alliances with Bristol-Myers Squibb, Regeneron, Warner Chilcott, and Regulus Therapeutics Inc., as well as a strategic collaboration with UCB S.A. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1970 and is headquartered in Paris, France.